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ORIGINAL ARTICLE
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Abstract
Context: Aqueous decoction of Hypoxis hemerocallidea Fisch. & C.A. Mey. (Hypoxidaceae)
(Hypoxis) is widely consumed in Southern Africa by people living with HIV/AIDS, some of whom
are on ARV and other medications.
Objective: The aim of this study was to investigate the potential of the crude aqueous extracts
of Hypoxis to inhibit major forms of CYP450 and transport proteins.
Materials and methods: Corms of Hypoxis were water-extracted and incubated (in graded
concentrations: 1–100 mg/mL) with human liver microsomes (20min) to monitor the effects
on phenacetin O-deethylation, coumarin 7-hydroxylation, bupropion hydroxylation, paclitaxel
6a-hydroxylation, diclofenac 40-hydroxylation, S-mephenytoin 40-hydroxylation, bufuralol
10-hydroxylation, chlorzoxazone 6-hydroxylation, midazolam 10-hydroxylation and testosterone
6b-hydroxylation as markers for the metabolic activities of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19,
2D6, 2E1 and 3A4/5, respectively. The generation of metabolites were monitored and
quantified with the aid of LC-MS/MS. The potential of the extracts to inhibit human ATP-
binding cassette transporter activity was assessed using recombinant MDCKII and LLC-PK1 cells
over-expressing human breast cancer resistant protein and human P-glycoprotein , respectively
(with Ko143 and cyclosporin A as positive controls). Similar assessment was performed with
human organic anion transporting polypeptide (OATP1B1 and OATP1B3) using recombinant
HEK293 cells over-expressing OATP1B1 and OATP1B3, respectively (with rifamycin and 10mM
atorvastatin as positive controls).
Results: Extracts of Hypoxis inhibited the production of the metabolites of the substrates of the
following enzymes (as compared to controls) with the indicated IC50 values (mg/mL): CYP1A2
(120.6), CYP2A6 (210.8), CYP2B6 (98.5), CYP2C8 (195.2), CYP2C9 (156) and CYP3A4/5 (185.4).
The inhibition of the uptake activity of OATP1B1 and OATP1B3 were also observed with IC50
values of 93.4 and 244.8 mg/mL, respectively.
Discussion: Extract concentrations higher than the estimated IC50 values are achievable in the
gastrointestinal tract when traditional doses of Hypoxis are considered. This may have profound
effects on presystemic metabolism of the drug substrates. If absorbed, systemic inhibition of
metabolic enzymes/transporters by Hypoxis may be expected.
Conclusion: The result suggests that there is the potential for HDI between Hypoxis and the
substrates of the affected enzymes/transporters, if sufficient in vivo concentration of Hypoxis
extracts is attained.
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Introduction
An estimated 80% of Africans are said to rely on traditional
medicine for the management of various pathological
conditions (UNAIDS, 2007). For the majority of this
group of individuals, consultation with traditional health
practitioners (THP) is the first call for health services (Babb
et al., 2007). Sexually transmitted infections, cardiovascular
disorders, psychiatry ailments, fever and skeletomuscular
pain are some of the common reasons why THPs are
consulted in Africa (Peltzer, 2001, 2003). The high burden
of HIV/AIDS, especially in Africa, has attracted various
government-backed policies designed to accommodate a
holistic management approach including the use of trad-
itional medicine. One such measure taken in South Africa is
the recommendation of Hypoxis hemerocallidea Fisch. &
C.A. Mey. (Hypoxidaceae) (Hypoxis) among other herbal
products, for people living with HIV/AIDS (Southern
African Development Community, 2003). This is in addition
to the introduction of free antiretroviral drugs (ARV). Thus,
while the use of medicinal herb, a principal component of
traditional medicine, predates the emergence of HIV/AIDS,
there is a widespread consumption of herbal products for the
management of HIV/AIDS either as complementary or
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alternative medicine (MacPhail et al., 2002; Malangu, 2007;
Mills et al., 2005; Morris, 2002).
One other reported reason for the popularity and wide
acceptability of herbal remedies by HIV/AIDS patients is the
perceived adverse reactions to ARVs, especially in compari-
son to the herbal products that are erroneously believed to be
free of side effects (Peltzer & Mngqundaniso, 2008). Cultural
and traditional beliefs have advanced traditional health
practices so that medicinal herbs are consumed as alternatives
to ARVs. It has been reported that, although the South
African National ARV Treatment Guidelines require patients
to disclose intake of any other medication including trad-
itional medicines to their healthcare providers, most patients
do not (South African Department of Health, 2004). Thus, the
number of HIV/AIDS patients who consume herbal medicine
alone or concomitantly with ARVs may have been under-
estimated. Peltzer et al. (2011) reported in a cross-sectional
study that up to 90% of respondents who were taking herbal
therapies for HIV did not disclose this to their health care
providers. Additionally, information on the therapeutic benefit
and/or toxicology of herb–drug combination is sparse. One of
the most important clinical consequences of such combina-
tions is herb–drug interaction (HDI). This can result from
herb-induced inhibition/induction of the metabolic enzymes
and drug transporters leading to the alteration in the
pharmacokinetic profiles of the ARVs. HDI in HIV/AIDS
management may significantly compromise the goal of
antiretroviral therapy and enhance toxicity and/viral resist-
ance to ARV.
Widely known as African potato, Hypoxis is one of the
most popular herbal remedies consumed among people living
with HIV/AIDS in South Africa to boost immunity and
enhance general well-being. It is a well-known genus of the
Hypoxidaceae family and referred to variously in local
languages as Afrika patat (Afrikaans), inkomfe (Zulu) and
ilabatheka (Xhosa) (Marandola et al., 1997).
A geophyte with bright yellow flowers giving it its common
name ‘‘yellow stars’’, Hypoxis has found to be used tradition-
ally in the treatment of benign prostatic hyperplasia in South
Africa (Buck, 1996; Lowe & Ku, 1996; Marandola et al.,
1997); as purgative and delirium remedy among the Zulus of
South Africa (Msonthi & Magombo, 1983); for the manage-
ment of abdominal pain, fever, anorexia and vomiting by the
Karanga people of Southern Africa (Watt & Breyer-Brandwijk,
1962); for uterine cancer in Swaziland (Amusan et al., 1995);
and for sexual-related disorders in Mozambique (Banderia
et al., 2001). Its major phytochemicals, beta-sitosterol,
hypoxoside and rooperol, have been investigated clinically
for cancer therapy (Albrecht et al., 1995; Berges et al., 1995;
Klippel et al., 1997; Smit et al., 1995). Various other studies of
the extracts in animal models have suggested antidiabetic
(Ojewole, 2006), anticonvulsant (Ojewole, 2008), antidiarrheal
(Ojewole et al., 2009a), anti-inflammatory (Ojewole, 2002),
antimicrobial (Ncube et al., 2012), antioxidant (Laporta et al.,
2007; Nair et al., 2007), bronchorelaxant (Ojewole et al.,
2009b), hypoglycaemic (Mahomed & Ojewole, 2003), hypo-
tensive (Ojewole et al., 2006) and uterolytic activity
(Nyinawumuntu et al., 2008).
Currently, the consumption of Hypoxis among HIV/
AIDS patients, most of who are on ARV, is popular
(Malangu, 2007). The safety of such concomitant adminis-
tration has not been demonstrated. This is necessary to
ascertain the presence or absence of the potential for HDI.
This may be mediated by the inhibition/induction of the
metabolic enzymes and/or drug transporters by the phyto-
chemical constituents of Hypoxis. HDI may be potentially
deleterious in people living with HIV/AIDS because of the
high number of medications used in antiretroviral therapy and
its co-morbidity. In vitro liver-based technologies have been
utilized to assess the potential for drug interactions with other
drugs, food or herbs. Such investigations provide predictive
mechanism for in vivo reality (Umehara & Camenisch, 2011).
Earlier investigation by Mills et al. (2005) using microsome-
based in vitro fluorometric microtitre plate assay had
suggested that extracts of Hypoxis are capable of inhibiting
the activity of CYP3A4 and P-glycoproteins. Information on
the influence of Hypoxis on other CYP isoforms and transport
proteins are generally lacking.
The current study therefore investigates the potential of the
crude extracts of Hypoxis to inhibit the nine major cyto-
chrome P450 (CYP) isozymes employing human liver
microsomes (HLM), two efflux and two uptake proteins
using cell lines expressing the transporter proteins.
Materials and methods
Plant materials
Fresh corms of Hypoxis were obtained in September 2010,
from two South African traditional health practitioners
(THPs) in Cape Town who identified the plant as ilabatheka
in local Xhosa language. The samples were identified with the
help of Kwaleta Sibuyile and Viola Kalitz of the Stellenbosch
University botanical garden. The sample specimens were
prepared and housed at the Division of Pharmacology,
University of Stellenbosch. Information on the mode of use,
dosage and specific HIV/AIDS-related indications were
obtained from the same THPs and documented through
semi-structured interview at the time of collection.
Ethical approval (as required because of the involvement
of the THPs) was obtained from the University of
Stellenbosch Health Research Ethics Committee with Ethics
reference number N10/09/307.
Chemical compounds
The chemical and bio-reagents used in this study were
obtained as follows: 10-hydroxybufuralol maleate, 40-hydro-
xymephenytoin, 6b-hydroxytestosterone and bufuralol hydro-
chloride from Ultrafine Chemicals (Pty) Ltd (Manchester,
UK); 6-hydroxychlorzoxazone, 7-hydroxycoumarin, acet-
aminophen, bupropion, chlorzoxazone, coumarin, furafylline,
NADPH, estradiol-17b-D-glucuronide (sodium salt), pacli-
taxel, tranylcypromine, troleandomycin (TAO), warfarin,
rifamycin, thioconazole, digoxin, cyclosporin A and testos-
terone from Sigma-Aldrich (Pty) Ltd (St. Louis, MO);
dimethylsulfoxide (DMSO), di-potassium hydrogen phos-
phate (K2HPO4), acetonitrile, formic acid and methanol
from Merck Chemicals (Pty) Ltd (Darmstadt, Germany);
[13C6] 4
0-hydroxydiclofenac, [13C6] 7-hydroxycoumarin,
[2H3] 4
0-hydroxymephenytoin, diclofenac and paroxetine
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from Novartis Pharma AG (Basel, Switzerland); hydroxybu-
propion, [2H6] hydroxybupropion and [
2H9] 1
0-hydroxybufur-
alol from BD Biosciences (Pty) Ltd (San Jose, CA); 6a-
hydroxypaclitaxel from Gentest BD Biosciences (Woburn,
MA); [2H3] 6b-hydroxytestosterone from Cerilliant Chemicals
(Pty) Ltd (Round Rock, TX); phenacetin, magnesium chloride
hexahydrate, ticlopidine hydrochloride and potassium dihy-
drogen phosphate (KH2PO4) from Fluka Chemicals (Pty) Ltd
(Buchs, Switzerland); 40-hydroxydiclofenac from Calbiochem
(Pty) Ltd (La Jolla, CA), (3 S,6 S,12aS)-1,2,3,4,6,7,12,12 a-
Octahydro-9-methoxy-6 -(2-methylpropyl)-1,4-dioxopyrazi-
no[10,20:1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-
dimethylethyl ester (Ko143) from Tocris Bioscience (Pty)
Ltd (Ellisville, MI); 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine-2 (PhIP) and its radio-labeled form (1.85 MBq/
nmol, radiochemical purity 499%) from Toronto Research
Chemicals (Pty) Ltd (North York, Canada); radio-labeled [3H]
digoxin (1.103 MBq/nmol, radiochemical purity497%) and
[3H]estradiol-17b-D-glucuronide (1.72 MBq/nmol, radio-
chemical purity497% from Perkin Elmer Radiochemicals
(Pty) Ltd (Waltham, MA); zosuquidar trihydrochloride
(LY335979) from Chembiotek (Pty) Ltd (Kolkata, India).
Other reagents were of analytical grade.
Assay enzymes and cells
Pooled mixed gender HLM prepared from 50 individual
donors with total CYP and cytochrome b5 content of
290 pmol/mg protein and 790 pmol/mg protein, respectively,
was obtained from Gentest BD Biosciences (Woburn, MA).
The catalytic activities of enzymes were provided by the
manufacturer.
Extraction of plant material
The air-dried and powdered corms of Hypoxis were extracted
with water in a round bottom flask. After the initial constant
stirring for 2 h, the mixture was allowed to extract for 24 h,
decanted, and centrifuged (20 000 rpm, 5 min). The super-
natant was filtered (0.45 mL; Whatman International LTD,
Maidstone, England) and freeze dried. The dried extract,
henceforth referred to as HP, was reconstituted in water and
stored at 20 C for further use.
Incubation in HLM
Thawed HLM were diluted with potassium phosphate buffer
(50 mM; pH¼ 7.4) and incubated in 96-well plate format.
Graded concentrations of HP were prepared in water such that
the addition of 1 mL to 200 mL incubation mixture yielded a
final extract concentration of 0.39, 0.78, 1.56, 3.13, 6.25,
12.5, 25, 50 and 100 mg/mL, respectively. Appropriate CYP
substrate (Table 1) was added and the mixture pre-incubated
at 37 C for 10 min using an IS89 96-well plate incubator
(Wesbart, Leimuiden, The Netherlands). Metabolic reactions
were initiated by adding NADPH (1 mM) and magnesium
chloride (5 mM) solution, and terminated after 20 min through
the addition of formic acid (10 mL; 50%). All incubations
were performed in duplicate. Control incubations contained
CYP-specific inhibitor, and incubations without inhibitors.
The final concentration of organic solvents in the incubations
was less than 0.5% (v/v). Probe substrate concentrations used
were less or equal to published Km values.
Quantitative analysis of metabolites
LC-MS methods were developed to simultaneously analyze
the metabolites of bupropion, paclitaxel, diclofenac and
bufuralol (Group A), phenacetin, coumarin and testosterone
(Group B); and S-mephenytoin with chlorzoxazone (Group C)
with the appropriate internal standard (Table 1). Total
separation and elution of the analytes were achieved within
10 min retention time, using the Luna Phenyl-Hexyl [3 mm,
inner dimensions 50 1 mm (Phenomenex, Torrance, CA)]
column (30 C), in a dual mobile phase of water and
acetonitrile (each containig 1% v/v formic acid), with a
gradient (group A) and isocratic (group B and C, 70:30) flow
set at 60 mL/min.
Before chromatographic analysis, samples were pooled
according to the groups and subjected to solid-phase extrac-
tion using OASIS HLB 96-well plate 30 mm (30 mg) elution
plate (Waters, Milford, MA). This was performed by sequen-
tial washing with 1 mL each of water and water-methanol (95/
5; v/v) followed by two-time elution with 1 mL methanol. The
elutes were dried employing the 96-well Micro-DS96 evap-
orator (Porvair Sciences Ltd., Shepperton, UK) at 37 C and
reconstituted in 100mL of 10% acetonitrile containing 0.1%
Table 1. Probe substrates, microsomal protein concentrations and incubation times.
Enzyme
Probe
substrate
Microsome
concentration
(mg protein/mL)
Probe substrate
concentration (mM)
Literature Km
value (mM) Internal standard
CYP1A2 Phenacetin 0.2 10 9.0a, 14b, 31c, 54d [2H4] acetaminophen
CYP2A6 Coumarin 0.2 2.5 0.5 [13C6]7-hydroxy-coumarin
CYP2B6 Bupropion 0.1 25 76e, 89f,130g [2H6] hydroxybupropion
CYP2C8 Paclitaxel 0.2 10 4.0h, 15i warfarin
CYP2C9 Diclofenac 0.1 5 3.4j, 9.0k [13C6] 4
0-hydroxy-diclofenac
CYP2C19 S-mephenytoin 0.5 30 51l, 42m, 31n [2H3] 4
0-hydroxy-mephenytoin
CYP2D6 Bufuralol 0.2 5 13o, 44p [2H9] 1
0-hydroxybufuralol
CYP2E1 Chlorzoxazone 0.5 10 22–49q [2H3] 4
0-hydroxy-mephenytoin
CYP3A4/5 Testosterone 0.2 30 50–60r, 51s [2H3] 6b-hydroxy-testosterone
aTassaneeyakul et al., 1993; bBrøsen et al., 1993; cVenkatakrishnan et al., 1998; dRodrigues et al., 1997; eFaucette et al., 2000; fHesse et al., 2000;
gLi et al., 2003; hRahman et al., 1994; iCresteil et al., 1994; jTranson et al., 1996; kBort et al., 1999; lColler et al., 1999; mVenkatakrishnan et al., 1998;
nSchmider et al., 1996; oBoobis et al., 1985; pYamazaki et al., 1994; qPeter et al., 1990; rDraper et al., 1998; sKenworthy et al., 2001.
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formic acid for LC-MS analysis. Enzyme activity was
measured in terms of the production of the CYP-specific
metabolite. Relative activity (100%) was defined in terms of
metabolite production in the absence of inhibitor. The enzyme
inhibition parameter (IC50) was calculated by employing the
kinetic equation for sigmoid curves (Equation 1) where
x¼ concentration; y¼ relative enzyme activity; and s¼ slope
factor.
y ¼ 100%
1 þ x
IC50
 2 : ð1Þ
Investigation of the inhibitory effects of Hypoxis on
P-gp and BCRP
HP was soluble up to a final concentration of 500 mg/mL
in P-gp and BCRP uptake buffers. LLC-PK1 cells stably
transfected with human P-gp were grown and maintained
in Medium 199 supplemented with 10% FBS, 50 ng/mL
gentamycin and 100 ng/mL hygromycin B at 37C under an
atmosphere of 5% CO2. MDCKII cells stably transfected
with human BCRP were grown and maintained in DMEM
supplemented with 10% FBS, 1% L-glutamine and 1%
penicillin/streptomycin at 37C under an atmosphere of 5%
CO2. Cells ( 0.6 105 cells per well for LLC-PK1-P-gp
and MDCKII-BCRP transfectants) were seeded into
Falcon

clear bottom 96-well plates (Becton Dickinson)
with 200mL of culture medium and the assay was
performed after 24 h.
Graded concentrations of HP were prepared in HBSS
containing 12.5 mM HEPES adjusted with HCl to pH 7.4 (for
P-gp) and OPTIMEM containing 12.5 mM HEPES adjusted to
pH 7.8 (for BCRP). The assay procedure was begun by the
aspiration and replacing the culture medium with pre-
incubation uptake buffer system containing HP or the specific
inhibitors as positive control (10mM cyclosporin A for P-gp
and 1 mM Ko143 for BCRP). Plates were subsequently
incubated at 37 C for 10 min. Transporter-mediated uptake
was initiated by the addition of the radiolabeled probe
substrates (1 mM digoxin for P-gp and 1 mM PhIP for BCRP).
The uptake reaction was terminated after 40 min by removing
the incubation solution. The cells were then washed twice
with ice-cold PBS buffer and monolayer integrity was
assessed optically. This is followed by the dissolution of the
cells by the addition on 0.2 N NaOH (200 mL per well) and
20 min at 37C incubation. Dissolved cells were then
transferred to scintillation vials containing scintillation cock-
tail and uptaken substrates were determined using the
scintillation counter.
All uptake studies were performed in triplicate in an
incubator without shaking. Methanol/DMSO was always
below 1%v/v of the total volume and all solutions used in
cell growth were maintained at the appropriate pH.
Investigation of the inhibitory effects of Hypoxis on
OATP1B1 and OATP1B3
HEK293 cells stably transfected with human OATP1B1
were grown and maintained in DMEM supplemented with
10% FBS, 1% L-glutamine, 1% penicillin/streptomycin, and
50 ng/mL hygromycin B at 37C under an atmosphere of 5%
CO2. HEK293 cells stably transfected with human OATP1B3
were grown and maintained in DMEM supplemented with
10% FBS, 1% L-glutamine, 1% penicillin/streptomycin and
0.8 mg/mL G418 at 37C under an atmosphere of 5% CO2.
Cells ( 0.2 106 cells per well) for overexpressing
OATP1B1 and OATP1B3 were seeded into pre-coated
(poly-L-lysine, poly-L-ornitin, 0.1 mg/mL) clear bottom 96
well plates (Corning Product No 734-1795) with 200 mL of
culture medium. Graded concentrations of HP were prepared
in HBSS containing 12.5 mM HEPES adjusted with HCl to
pH 7.4. Uptake studies, performed 72 h after seeding was
started by aspirating and replacing the culture medium with
the final incubation buffer system containing HP or the
positive control inhibitor (20mM rifamycin and 10 mM
atorvastatin). The uptake reactions were terminated after
5 min by removing the incubation solution. Subsequently, the
wells were washed twice with ice-cold PBS buffer and
monolayer integrity was assessed optically. Radioactive
samples were analyzed by liquid scintillation counting in a
similar procedure as described above. All uptake studies were
performed in triplicate in an incubator without shaking.
Drug uptake clearance calculations
Probe substrate uptake clearance (nL/min/mg protein) by
the stably transfected cells expressing the transporter
proteins was determined from the specific amount of
radiolabeled probe substrate inside the cells divided by the
concentration in the incubation medium and normalized to
the incubation time and the mean protein concentration
measured in test wells.
Absolute transporter uptake data were converted into
relative inhibition values by defining membrane permeability
of the probe substrate in the absence of inhibitor as 0%
inhibition while the positive control exerted 100% transporter
inhibition. Relative inhibition (%) was profiled against
inhibitor concentration and the IC50 calculated using the
nonlinear-regression method.
The IC50 values (inhibitor concentration that causes 50%
inhibition of the maximal drug effect) were calculated using
the following equation:
y ¼ y0 þ a  I
n
IC50n þ In ð2Þ
where n is the slope factor (Hill coefficient), y0 is the
relative baseline inhibition and a is the maximal transporter
inhibition (%).
Results
Influence of HP on the metabolic activity of CYPs
A concentration-dependent inhibition of CYP1A2, CYP2A6,
CYP2B6, CYP2C8, CYP2C9 and CYP3A4/5 was observed
with HP. The extract concentration profiled against relative
enzyme activity is shown in Figures 1 and 2. The estimated
IC50 values are presented in Table 2. Within the concentration
tested (100 mg/mL), no significant inhibition of CYP2C19,
CYP2D6 and CYP2E1 was observed.
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Influence of Hypoxis on transport proteins
The uptake activity of OATP1B1 and OATP1B3 was inhibited
by HP in a concentration-dependent manner. No inhibitory
activity of P-gp and BCRP was observed with up to
500mg/mL of HP. The effect of increasing concentration of
HP on the activity of the transport proteins is illustrated in
Figures 3 and 4. An overall summary is provided in Table 3.
Discussion
The popularity of Hypoxis hemerocallidea as a medicinal herb
in Africa, especially among people living with HIV/AIDS,
most of who are on ARV, increases the likelihood for its
combination with ARV. Additionally, its other traditional
indications may encourage its use with orthodox medicines
used for the treatment of such diseases. The obvious risk of
HDI in herb-drug combination is worth considering especially
with Hypoxis; as such information is not available. Thus, this
study presents the first comprehensive evaluation of the
effects of Hypoxis on the activity of important P450s and
transport proteins.
Hypoxis was obtained from THPs for this study. THPs
are considered representative source of Hypoxis to reflect
the actual practice of patients’ patronage. Although, some
products of Hypoxis are now available in open shops, the
majority of Africans, for cultural and traditional reasons,
consult THP to obtain it. The samples were water-extracted.
This is because, as obtained from the consulted THPs, the
popular mode of Hypoxis use is as aqueous decoction.
Thus, the patients are exposed to the water-extracted
constituents.
While various liver-based technologies are available for
assessing drug–drug and HDI, HLM is the most common, and
well-accepted. It has been widely used to assess the HDI
potential of a number of herbal products. The outcome of such
studies provides an indication for clinically significant
interactions. Results from in vitro metabolic studies have
been extrapolated for in vivo correlation with high degree of
predictability (Tassaneeyakul, 1993). The use of HLM with
CYP-specific substrates, while monitoring the production
(through identification and quantification) of metabolites
from CYP-specific probe reactions as we did, is considered
closer to humans (in terms of results interpretation) than the
methods of Mills et al. (2005). Our study is therefore
significantly different in scope, methodology and compre-
hensiveness than earlier similar studies.
Figure 1. Effect of the extracts of Hypoxis hemerocallidea on (A) CYP1A2-mediated phenacetin deethylation; (B) CYP2A6-mediated coumarin 7-
hydroxylation, and (C) CYP2B6-mediated bupropion hydroxylation.
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In the average, about 1000 mg of Hypoxis is extracted for
singular consumption. The achievable gastrointestinal con-
centration is higher than the determined IC50 values for the
enzymes/transported that were inhibited in this study
(Table 4). This can have potential deleterious effects on
intestinal CYP and transporters with attendant effects on drug
absorption. Drugs like the viral protease inhibitors, calcium
channel receptor blockers, various chemotherapeutic agents,
statins, for example, undergo significant pre-systemic intes-
tinal metabolism. The inhibition of the intestinal CYP may
alter the pharmacokinetic profile of such drugs with the
potential of exceeding safety margins. This will be more
important for drugs with narrow therapeutic window.
The inhibitory effects observed in this study were based on
singular exposure of the enzymes to the herbal extract. In
reality, herbal products are consumed repetitively over a long
Figure 2. Effect of the extracts of Hypoxis hemerocallidea on (A) CYP2C8-mediated paclitaxel 6a-hydroxylation; (B) CYP2C9-mediated diclofenac
40-hydroxylation, and (C) CYP3A4/5-mediated testosterone 6b-hydroxylation in pooled human liver microsomes.
Figure 3. Effect of varying concentrations of the extracts of Hypoxis
hemerocallidea on estradiol-17b-D-glucuronide uptake by OATP1B1
expressing HEK293 cells. The line represents the ‘‘best fit’’ of the data
to the equation 2 (R2¼ 0.99) which are averages of triplicate determin-
ations and the bars represent the standard deviations.
Table 2. The potency of inhibitory effects of HP on CYP expressed in
IC50 values.
CYP enzyme Probe reaction IC50 value (mg/mL)
CYP1A2 Phenacetin O-deethylation 120.6 5.1
CYP2A6 Coumarin 7-hydroxylation 210.8 8.5
CYP2B6 Bupropion hydroxylation 98.5 3.3
CYP2C8 Paclitaxel 6a-hydroxylation 195.2 3.8
CYP2C9 Diclofenac 40-hydroxylation 156.0 4.5
CYP2C19 S-Mephenytoin 40-hydroxylation n.i.o.
CYP2D6 Bufuralol 10-hydroxylation n.i.o.
CYP2E1 Chlorzoxazone 6-hydroxylation n.i.o.
CYP3A4/5 Testosterone 6b-hydroxylation 185.4 9.3
n.i.o.¼ no inhibition observed.
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period of time. The effects on metabolic enzymes may be
more pronounced.
Information on the bioavailability of the extracts or
constituents of Hypoxis is not available. Thus, it is difficult
to predict the effects on systemic CYP and transporters.
However, with claims of its systemic activity as immune
booster and for other systemic indications, its phyto-
constituents are expected to be absorbed for efficacy. Since
OATP1B1 and OATP1B3 are located at the sinusoidal
membrane of the liver, the inhibitory effects of Hypoxis on
the OTA1B1 and OTP1B3 will only be important if there is
absorption. Absorbed constituents may thus inhibit systemic
CYPs, OATP1B1 and 1B3 with consequent alteration of the
pharmacokinetic profile of co-administered drugs.
With the increasing popularity of herbs among people who
also consume orthodox medications in Africa, it is important
to understand the potential for HDI. Such information will be
useful to health care professionals, the consuming public and
policy makers.
There are few factors that may limit the clinical applic-
ability of this study. Hypoxis was obtained from THPs just as
their clients do. Aqueous extracts were also used to reflect the
popular use of water-decoctions in reality. Thus, the approach
adopted in this study represents the popular practice in source
and use. Variations in phytochemical composition of herbs are
known to occur depending on the place and time of harvest.
Such variation is not accounted for in this study. In addition,
there are commercial forms of Hypoxis including capsules of
dried powdered corms. The consumption of such capsules
may expose consumers to non-water-soluble constituents.
The range of extract concentration tested is arbitrary and
methodology-limited. This is because information on the
achievable plasma levels of the extracts is not available. The
exact active phytochemicals exerting the inhibitory effects is
not known. Although in vitro HDI studies are the main
source of information on the potential for in vivo HDI,
in vivo human studies are the ultimate proof of clinically
significant HDI.
Hypoxis may inhibit the metabolic clearance of
co-medications metabolized by CYP1A2, CYP2A6,
CYP2B6, CYP2C8, CYP2C9, CYP3A4/5, OATP1B1 and
OATP1B3 if sufficient in vivo concentration is achieved.
This presents a potential for pharmacokinetic HDI if Hypoxis
is consumed with drug substrates of these enzymes and/or
transporters. Within the concentration tested, Hypoxis is not
expected to inhibit human CYP2C19, CYP2D6, CYP2E1,
P-gp or BCRP. It is therefore advisable to take caution in
Hypoxis-ARV combination use.
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Table 3. Summary of inhibitory effects of HP on transporter proteins.
Transporter Probe substrate IC50 value
a,b (mg/mL) Kic (mg/mL) Max. inhibitionb,d (%)
P-gp Digoxin Not observed Not applicable Not observed
BCRP PhIP Not observed Not applicable Not observed
OATP1B1 Estradiol-17b-D-glucuronide 118.7 33.3 93.44 71.29d
OATP1B3 Estradiol-17b-D-glucuronide 290.1 59.7 244.79 93.95d
aHP concentration estimated to inhibit transporter activity by 50%; bData used for curve fitting are mean SD of N¼ 3.
cCalculated with Ki¼ IC50/(1þ S/Km), where S is the substrate concentration of the probe substrate and Km is the transporter
affinity of the probe substrate according to Michaelis–Menten.
dMaximal observed inhibition with respect to positive control.
Figure 4. Effect of varying concentration of the extracts of Hypoxis
hemerocallidea on estradiol-17b-D-glucuronide uptake by OATP1B3
expressing HEK293 cells. The line represents the ‘‘best fit’’ of the data
to the equation 2 (R2¼ 0.98) which are averages of triplicate determin-
ations and the bars represent the standard deviations.
Table 4. Interpretation of the in vitro findings.
Part used in traditional practice Leaves
Usual human dose (single; mg) 1000
Extraction yield (%w/w) 12.6
Estimated extract per dose (mg) 126
Putative GIT concentration (mg/mL)a 504
In vitro IC50 range (mg/mL) 98–244
Potential for clinically significant HDIb Yes
aEstimated GIT fluid¼ 250 mL, with the assumption that the 60%
methanol-soluble extracts are extracted in the GIT.
bThis refers to HDI in the GIT with possible effects on drug absorption.
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